Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Stomach Neoplasms 1Skin Neoplasms 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Poly I-C × Clear all
NCT00094003 2005-11-11

Study of NS-9 in Patients With Liver Metastases

NS Pharma, Inc.

Phase 1 Completed
20 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡